ArticleThe Journal of clinical investigation2025
Fusobacterium nucleatum promotes colorectal cancer through neogenesis of tumor stem cells.
Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- The gut microbiota as a regulator of intestinal stem-cell fate: bacterial and fungal control of differentiation and regeneration.Gut microbes · 2026Review
- Age-Related and Lifestyle-Related Differences in Gut Microbiota Composition Among Community-Dwelling Adults.Microorganisms · 2026Article
- Article
- Single-cell and spatial transcriptomic landscapes reveal PIGT as a pivotal regulator of immunometabolic remodeling in colorectal cancer liver metastasis.Functional & integrative genomics · 2026Article
- Xylitol, Mitochondrial Plasticity, the Warburg Effect, and Oral Pathobiont-Associated Immune Evasion in Cancer Hypothesis.International journal of molecular sciences · 2026Review
- Microbial Dynamics across Molecular Subtypes and Prognostic Significance of Lactobacillus in Gastric Cancer.Cancer research and treatment · 2026Article
- Inflammation and Colorectal Cancer Pathogenesis: Molecular, Immunological, and Environmental Features for Therapy Response and Resistances.International journal of molecular sciences · 2026Review
- Pathogenic Roles ofPathogens (Basel, Switzerland) · 2026Review
- Microbial crosstalk along the oral-gut axis: organ-specific oncogenic adaptations of Porphyromonas gingivalis and Fusobacterium nucleatum.Neoplasia (New York, N.Y.) · 2026Review
- Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances.Molecular biomedicine · 2026Review
- Intratumoral microbiome: the double-edged sword in remodeling cancer immunotherapy.Molecular cancer · 2026Review
- Fecal metagenomic profiling in patients with colorectal adenomas to characterize gut microbial composition and functional potential.Frontiers in microbiology · 2026Article
- The Gut Microbiome and Colorectal Cancer: From Association to Causation.Cancer biome and targeted therapy · 2026Article
- Intestinal stem cells as innate immune sentinels: coupling environmental sensing to epithelial adaptation.Frontiers in immunology · 2026Review
- Tumor-Promoting Gut Microbes in Colorectal Cancer: Mechanisms and Translational Perspectives.International journal of medical sciences · 2026Review
- Intratumoral microbiota: implications for colorectal cancer pathogenesis and therapy.Frontiers in immunology · 2026Review
- Nanodynamic Therapy in Colorectal Cancer: Engineering Precision Immunotherapy and Multimodal Synergy.International journal of nanomedicine · 2026Review
- Association of multi-site microbial features with malignancy risk in pulmonary ground-glass nodules and identification of predictive biomarkers: a prospective multicenter cohort study.Journal of translational medicine · 2025Article
- Integrative pan-cancer analysis of intratumoral microbial communities for biomarker discovery and diagnostic modeling.Journal of translational medicine · 2025Article
- Characterization of the microbial profile in tears of patients with primary open-angle glaucoma: results from a pilot study.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal stem cells are crucial for maintaining intestinal homeostasis, yet their transformation into tumor stem cells in the context of microbial infection remains poorly understood. Fusobacterium nucleatum is frequently associated with the onset and progression of colorectal cancer (CRC). In this study, we uncovered that F. nucleatum colonized the depths of gut crypts in both patients with CRC and mouse models. Through single-cell sequencing analysis, we demonstrated that F. nucleatum infection reprogrammed crypt cells and activated lymphocyte antigen 6 complex, locus A+ ( LY6A+, also known as stem cell antigen 1 [Sca-1]) revival stem cells (RSCs), promoting their hyperproliferation and subsequent transformation into tumor stem cells, which accelerated intestinal carcinogenesis. Mechanistically, we identified LY6A as a glycosylphosphatidylinositol-anchored (GPI-anchored) membrane receptor for F. nucleatum. Upon binding, F. nucleatum induced the upregulation of ribosomal protein S14 (RPS14) via the LY6A receptor, driving RSC hyperactivity and tumorigenic conversion. Functional studies showed that genetic ablation of Ly6a in intestinal epithelial cells or Rps14 in LY6A+ RSCs substantially reduced F. nucleatum colonization and tumorigenesis. Moreover, analysis of clinical CRC cohorts revealed a strong correlation between F. nucleatum infection, RSC expansion, and elevated RPS14 expression in tumor tissues. These findings highlight an alternative F. nucleatum/LY6A/RPS14 signaling axis as a critical driver of CRC progression and propose potential therapeutic targets for effective CRC intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.